SEC Info - Szostak M Anne - ‘4’ for 5/29/20 re: Idexx Laboratories Inc./DE

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

SZOSTAK M ANNE

(Last)

(First)

(Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK

04092

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
5/29/20

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	5/29/20		M		7,722	A	$63.95	7,722	D
Common Stock	5/29/20		G		7,722	D	$0	0	D
Common Stock	5/29/20		G		7,722	A	$0	7,722	I	M. Anne Szostak Trust ⁽¹⁾
Common Stock	5/29/20		S		2,980	D	$306.1191 ⁽³⁾	4,742	I	M. Anne Szostak Trust ⁽¹⁾
Common Stock	5/29/20		S		3,052	D	$307.021 ⁽⁴⁾	1,690	I	M. Anne Szostak Trust ⁽¹⁾
Common Stock	5/29/20		S		1,690	D	$308.0814 ⁽⁵⁾	0	I	M. Anne Szostak Trust ⁽¹⁾
Common Stock								10,217	I	2020 Szostak IDEXX GRAT ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right-to-buy)	$63.95	5/29/20		M			7,722	⁽⁶⁾	5/5/25	Common Stock	7,722	⁽⁷⁾	0	D

Explanation of Responses:

(1) The reporting person is the settlor of the M. Anne Szostak Trust ("Trust"), the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust.

(2) The reporting person is the settlor and trustee of the 2020 Szostak IDEXX GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.

(3) Represents the weighted average price of the shares sold ranging from a low of $305.53 to a high of $306.52 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

(4) Represents the weighted average price of the shares sold ranging from a low of $306.67 to a high of $307.40 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

(5) Represents the weighted average price of the shares sold ranging from a low of $307.72 to a high of $308.49 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

(6) Grant of option to buy 3,861 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one annual installment on May 6, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

(7) Not applicable.

	/s/ Lily J. Lu, Attorney-in-Fact for M. Anne Szostak	6/2/20
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

____________ Transaction Codes:
G	Bona fide gift.
M	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
S	Open market or private sale of non-derivative or derivative security.

Szostak M Anne – ‘4’ for 5/29/20 re: Idexx Laboratories Inc./DE

On: Tuesday, 6/2/20, at 5:00pm ET · For: 5/29/20 · Accession #: 1567619-20-11544 · File #: 0-19271

Previous ‘4’: ‘4’ on 5/22/20 for 5/20/20 · Next: ‘4’ on / for 11/10/20 · Latest: ‘4’ on 5/19/23 for 5/17/23

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34
Filing Table of Contents

This ‘4’ Document is an XML Data File that may be rendered in various formats:

Szostak M Anne – ‘4’ for 5/29/20 re: Idexx Laboratories Inc./DE

On: Tuesday, 6/2/20, at 5:00pm ET · For: 5/29/20 · Accession #: 1567619-20-11544 · File #: 0-19271

Previous ‘4’: ‘4’ on 5/22/20 for 5/20/20 · Next: ‘4’ on / for 11/10/20 · Latest: ‘4’ on 5/19/23 for 5/17/23

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34Filing Table of Contents

This ‘4’ Document is an XML Data File that may be rendered in various formats:

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34
Filing Table of Contents